|
IPO Preview: ContraFect (CFRX)
Seeking Alpha (registration) Biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. High price to book, 5.6. High cash burn … ContraFect Announces Pricing of Its Initial Public OfferingMarketwired (press release) IPO Report: ContraFect (CFRXU)Equities.com |
